Low Dose Spironolactone Monotherapy in the Management of Stage I Essential Hypertension: A Pilot Randomized, Double-Blind, Placebo-Controlled Trial

Overview

Journal Acta Cardiol Sin

Date 2018 Jan 30

PMID 29375225

Citations 14

Authors

Armin Attar

Amir-Abbas Sadeghi

Fatemeh Amirmoezi

Kamran Aghasadeghi

Affiliations

Soon will be listed here.

Abstract

Background: High blood pressure (BP) is a common chronic disease needs long life drug consumption to control. Spironolactone could be used as the fourth-line therapy in patients with resistant hypertension. However, there is no study to determine the effects of low dose spironolactone as a first line therapy in treatment of essential hypertension. The aim of this study is to investigate the effect of low dose spironolactone monotherapy in management of essential hypertension.

Methods: In this double blind randomized clinical trial, 40 patients who had stage I essential hypertension were randomly divided into two groups: intervention group received spironolactone 25 milligram once daily for one month and control group received placebo once daily. At the baseline and after one month, 24-hour BP holter-monitoring and serum potassium assay were done.

Results: Systolic BP was reduced from 143.5 ± 8.2 mmHg to 137.10 ± 7.57 mmHg in the intervention group, while it did not change significantly in control (between group treatment difference = -4.5 mmHg, p = 0.004). There was no significant reduction of diastolic BP in the intervention group in comparison to placebo group (between group treatment difference = -1.3 mmHg, p = 0.099).

Conclusions: Short course monotherapy with low dose spironolactone is effective in reducing systolic BP in patients with stage I essential hypertension.

Citing Articles

Factors associated with treatment and control of hypertension among elderly adults in Shenzhen, China: a large-scale cross-sectional study.

Ni W, Yuan X, Zhang J, Li P, Zhang H, Zhang Y BMJ Open. 2021; 11(8):e044892.

PMID: 34400442 PMC: 8370538. DOI: 10.1136/bmjopen-2020-044892.

The Effects of Intensive Blood Pressure Control on Cardiovascular Outcomes Based on 10-Year ASCVD Risk Score: An Analysis of a Clinical Trial.

Alborzi A, Attar A, Sayadi M, Nouri F Cardiol Res Pract. 2021; 2021:6635345.

PMID: 34055403 PMC: 8133861. DOI: 10.1155/2021/6635345.

Association of coronary artery dominance and mortality rate and complications in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention.

Mikaeilvand A, Firuozi A, Basiri H, Varghaei A, Izadpanah P, Kojuri J J Res Med Sci. 2021; 25:107.

PMID: 33824672 PMC: 8019104. DOI: 10.4103/jrms.JRMS_414_19.

J-shaped relationship between cardiovascular risk and efficacy of intensive blood pressure reduction: A post-hoc analysis of the SPRINT trial.

Attar A, Nouri F, Borazjani R, Sayadi M PLoS One. 2020; 15(10):e0240102.

PMID: 33002071 PMC: 7529282. DOI: 10.1371/journal.pone.0240102.

Prevalence, Treatment, Control and Monitoring of Hypertension: A Nationwide Community-Based Survey in Taiwan, 2017.

Pan H, Lin H, Chen W, Wang T Acta Cardiol Sin. 2020; 36(4):375-381.

PMID: 32675930 PMC: 7355114. DOI: 10.6515/ACS.202007_36(4).20191220A.

References

Tam T, Wu M, Masson S, Tsang M, Stabler S, Kinkade A . Eplerenone for hypertension. Cochrane Database Syst Rev. 2017; 2:CD008996. PMC: 6464701. DOI: 10.1002/14651858.CD008996.pub2. View

Aghajani M, Ajorpaz N, Kafaei Atrian M, Raofi Z, Abedi F, Naeimi Vartoni S . Effect of self - care education on quality of life in patients with primary hypertension: comparing lecture and educational package. Nurs Midwifery Stud. 2014; 2(4):71-6. PMC: 4228907. DOI: 10.5812/nms.11655. View

Jeunemaitre X, Chatellier G, Kreft-Jais C, Charru A, deVries C, Plouin P . Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol. 1987; 60(10):820-5. DOI: 10.1016/0002-9149(87)91030-7. View

Parsanezhad M, Attar A, Namavar-Jahromi B, Khoshkhou S, Khosravi-Maharlooei M, Monabati A . Changes in endothelial progenitor cell subsets in normal pregnancy compared with preeclampsia. J Chin Med Assoc. 2015; 78(6):345-52. DOI: 10.1016/j.jcma.2015.03.013. View

Engbaek M, Hjerrild M, Hallas J, Jacobsen I . The effect of low-dose spironolactone on resistant hypertension. J Am Soc Hypertens. 2010; 4(6):290-4. DOI: 10.1016/j.jash.2010.10.001. View

Briet M, Schiffrin E . Vascular actions of aldosterone. J Vasc Res. 2012; 50(2):89-99. DOI: 10.1159/000345243. View

Lane D, Shah S, Beevers D . Low-dose spironolactone in the management of resistant hypertension: a surveillance study. J Hypertens. 2007; 25(4):891-4. DOI: 10.1097/HJH.0b013e328014954d. View

Attar A, Khosravi Maharlooi M, Khoshkhou S, Hosseini A, Jaberipour M, Dehghan A . Colony forming unit endothelial cells do not exhibit telomerase alternative splicing variants and activity. Iran Biomed J. 2013; 17(3):146-51. PMC: 3770257. DOI: 10.6091/ibj.1100.2013. View

Vaclavik J, Sedlak R, Plachy M, Navratil K, Plasek J, Jarkovsky J . Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension. 2011; 57(6):1069-75. DOI: 10.1161/HYPERTENSIONAHA.111.169961. View

10.

Konishi Nishizaka M, Zaman M, Calhoun D . Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens. 2003; 16(11 Pt 1):925-30. DOI: 10.1016/s0895-7061(03)01032-x. View

11.

Attar A, Eslaminejad M, Tavangar M, Karamzadeh R, Dehghani-Nazhvani A, Ghahramani Y . Dental pulp polyps contain stem cells comparable to the normal dental pulps. J Clin Exp Dent. 2014; 6(1):e53-9. PMC: 3935906. DOI: 10.4317/jced.51305. View

12.

Sarafidis P, Bakris G . Resistant hypertension: an overview of evaluation and treatment. J Am Coll Cardiol. 2008; 52(22):1749-57. DOI: 10.1016/j.jacc.2008.08.036. View

13.

Batterink J, Stabler S, Tejani A, Fowkes C . Spironolactone for hypertension. Cochrane Database Syst Rev. 2010; (8):CD008169. DOI: 10.1002/14651858.CD008169.pub2. View

14.

Rahimi K, Emdin C, MacMahon S . The epidemiology of blood pressure and its worldwide management. Circ Res. 2015; 116(6):925-36. DOI: 10.1161/CIRCRESAHA.116.304723. View

15.

Wolf R, MENDLOWITZ M, ROBOZ J, Styan G, KORNFELD P, Weigl A . Treatment of hypertension with spironolactone. Double-blind study. JAMA. 1966; 198(11):1143-9. View

16.

Sternlicht H, Bakris G . Spironolactone for resistant hypertension--hard to resist?. Lancet. 2015; 386(10008):2032-2034. DOI: 10.1016/S0140-6736(15)00264-0. View

17.

Soberman J, Weber K . Spironolactone in congestive heart failure. Curr Hypertens Rep. 2000; 2(5):451-6. DOI: 10.1007/s11906-000-0027-x. View

18.

Messerli F, Williams B, Ritz E . Essential hypertension. Lancet. 2007; 370(9587):591-603. DOI: 10.1016/S0140-6736(07)61299-9. View

19.

Ouzan J, Perault C, Lincoff A, Carre E, Mertes M . The role of spironolactone in the treatment of patients with refractory hypertension. Am J Hypertens. 2002; 15(4 Pt 1):333-9. DOI: 10.1016/s0895-7061(01)02342-1. View

20.

Babaee Beigi M, Zibaeenezhad M, Aghasadeghi K, Jokar A, Shekarforoush S, Khazraei H . The effect of educational programs on hypertension management. Int Cardiovasc Res J. 2014; 8(3):94-8. PMC: 4109043. View